{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:22:05Z","timestamp":1780572125144,"version":"3.54.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>IV ciclosporin therapy is effective in steroid-refractory ulcerative colitis. The optimal drug level to achieve response and minimize complications during induction therapy is not known.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>The primary aim was to evaluate if serum ciclosporin drug levels are associated with increased risk of colectomy within 90 days of hospitalization. Secondary aims were to determine if ciclosporin levels are associated with avoidance of colectomy at 7 and 30 days, if ciclosporin levels are associated with drug-related and postoperative complications, and if patient-specific factors are associated with response to ciclosporin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective analysis of 81 hospitalized patients with steroid-refractory ulcerative colitis treated with ciclosporin. Risk factors for colectomy within 7, 30, and 90 days, medication-specific and postoperative complications were compared by first, mean, and peak ciclosporin level during IV induction therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were 47 patients (58%) who underwent surgery. There were no differences between initial, mean, and peak ciclosporin levels among responders and nonresponders and treatment-related or postoperative complications. Responders within 90 days had lower C-reactive-protein levels (20mg\/L vs. 38mg\/L, P = 0.01), lower serum albumin concentrations (3.4g\/dL vs. 3.7g\/dL, P = 0.03), and higher rates of kidney injury (50% vs 17%, P = 0.002).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Initial, mean, and peak serum levels of ciclosporin did not correlate with response or toxicity. However, C-reactive-protein levels levels and kidney injury may be helpful in predicting clinical response to ciclosporin.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izx105","type":"journal-article","created":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T13:47:04Z","timestamp":1519912024000},"page":"1291-1297","source":"Crossref","is-referenced-by-count":4,"title":["Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy"],"prefix":"10.1093","volume":"24","author":[{"given":"Parita","family":"Patel","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Chicago Medical Center, S Maryland Avenue, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Yarur","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Medical College of Wisconsin, W. Wisconsin Ave., Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushila","family":"Dalal","sequence":"first","affiliation":[{"name":"Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago Medical Center, S Maryland Avenue, MC, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhi","family":"Sakuraba","sequence":"first","affiliation":[{"name":"Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago Medical Center, S Maryland Avenue, MC, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T","family":"Rubin","sequence":"first","affiliation":[{"name":"Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago Medical Center, S Maryland Avenue, MC, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B","family":"Hanauer","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Hanan","sequence":"first","affiliation":[{"name":"Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago Medical Center, S Maryland Avenue, MC, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura H","family":"Raffals","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Mayo Clinic, SW, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell D","family":"Cohen","sequence":"first","affiliation":[{"name":"Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago Medical Center, S Maryland Avenue, MC, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Pekow","sequence":"first","affiliation":[{"name":"Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago Medical Center, S Maryland Avenue, MC, Chicago, IL"},{"name":"Department of Medicine, University of Chicago Medical Center, S Maryland Avenue, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,3,1]]},"reference":[{"key":"2020043000063130100_CIT0001","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","article-title":"Cyclosporine in severe ulcerative colitis refractory to steroid therapy","volume":"330","author":"Lichtiger","year":"1994","journal-title":"N Engl J Med"},{"key":"2020043000063130100_CIT0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0016-5085(94)90054-X","article-title":"Course of ulcerative colitis: analysis of changes in disease activity over years","volume":"107","author":"Langholz","year":"1994","journal-title":"Gastroenterology"},{"key":"2020043000063130100_CIT0003","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1053\/j.gastro.2012.08.003","article-title":"Once-daily budesonide mmx\u00ae extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the core i study","volume":"143","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"2020043000063130100_CIT0004","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/gutjnl-2012-304258","article-title":"Once-daily budesonide mmx in active, mild-to-moderate ulcerative colitis: results from the randomised core ii study","volume":"63","author":"Travis","year":"2014","journal-title":"Gut"},{"key":"2020043000063130100_CIT0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4067\/S0034-98872017000100013","article-title":"[Management of severe ulcerative colitis: an up-to-date]","volume":"145","author":"Hern\u00e1ndez-Rocha","year":"2017","journal-title":"Rev Med Chil"},{"key":"2020043000063130100_CIT0006","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(12)61084-8","article-title":"Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial","volume":"380","author":"Laharie","year":"2012","journal-title":"Lancet"},{"key":"2020043000063130100_CIT0007","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1053\/gast.2001.23983","article-title":"Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis","volume":"120","author":"D\u2019Haens","year":"2001","journal-title":"Gastroenterology"},{"key":"2020043000063130100_CIT0008","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-230X-7-13","article-title":"Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study","volume":"7","author":"Actis","year":"2007","journal-title":"BMC Gastroenterol"},{"key":"2020043000063130100_CIT0009","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/j.1572-0241.1999.01149.x","article-title":"Intravenous cyclosporin in ulcerative colitis: a five-year experience","volume":"94","author":"Cohen","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"2020043000063130100_CIT0010","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/0140-6736(90)91521-B","article-title":"Preliminary report: cyclosporin in treatment of severe active ulcerative colitis","volume":"336","author":"Lichtiger","year":"1990","journal-title":"Lancet"},{"key":"2020043000063130100_CIT0011","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/01.mib.0000235096.78736.8e","article-title":"Treatment of ulcerative colitis refractory to steroid therapy by oral microemulsion cyclosporine (neoral)","volume":"12","author":"Weber","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"2020043000063130100_CIT0012","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00054725-200105000-00001","article-title":"Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study","volume":"7","author":"Sands","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"2020043000063130100_CIT0013","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1055\/s-2007-963393","article-title":"[Use of infliximab in ulcerative colitis]","volume":"45","author":"Tilg","year":"2007","journal-title":"Z Gastroenterol"},{"key":"2020043000063130100_CIT0014","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1053\/j.gastro.2005.03.003","article-title":"Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study","volume":"128","author":"J\u00e4rnerot","year":"2005","journal-title":"Gastroenterology"},{"key":"2020043000063130100_CIT0015","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"2020043000063130100_CIT0016","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/jgh.13674","article-title":"Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis: a network meta-analysis","volume":"32","author":"Komaki","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"2020043000063130100_CIT0017","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2468-1253(16)30003-6","article-title":"Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (construct): a mixed methods, open-label, pragmatic randomised trial","volume":"1","author":"Williams","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2020043000063130100_CIT0018","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0016-5085(03)01214-9","article-title":"Randomized, double-blind comparison of 4 mg\/kg versus 2 mg\/kg intravenous cyclosporine in severe ulcerative colitis","volume":"125","author":"Van Assche","year":"2003","journal-title":"Gastroenterology"},{"key":"2020043000063130100_CIT0019","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0025-6196(11)64838-6","article-title":"Changing referral patterns for surgical treatment of ulcerative colitis","volume":"71","author":"Goudet","year":"1996","journal-title":"Mayo Clin Proc"},{"key":"2020043000063130100_CIT0020","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1751-2980.2011.00560.x","article-title":"Management of acute, severe ulcerative colitis","volume":"13","author":"Sachar","year":"2012","journal-title":"J Dig Dis"},{"key":"2020043000063130100_CIT0021","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jamcollsurg.2006.12.044","article-title":"Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis","volume":"204","author":"Selvasekar","year":"2007","journal-title":"J Am Coll Surg"},{"key":"2020043000063130100_CIT0022","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/01.mog.0000196151.74819.8e","article-title":"Complications of biological therapy for inflammatory bowel diseases","volume":"22","author":"Blonski","year":"2006","journal-title":"Curr Opin Gastroenterol"},{"key":"2020043000063130100_CIT0023","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1590\/0102-6720201600030017","article-title":"management of acute severe ulcerative colitis: a clinical update","volume":"29","author":"Sobrado","year":"2016","journal-title":"Arq Bras Cir Dig"},{"key":"2020043000063130100_CIT0024","first-page":"1424","article-title":"Cyclosporin for severe ulcerative colitis: a user\u2019s guide","volume":"92","author":"Kornbluth","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"2020043000063130100_CIT0025","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1046\/j.1365-2036.2003.01618.x","article-title":"Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis","volume":"18","author":"Rayner","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"2020043000063130100_CIT0026","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1046\/j.1365-2036.2002.01385.x","article-title":"Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis","volume":"16","author":"Dom\u00e8nech","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"2020043000063130100_CIT0027","doi-asserted-by":"crossref","first-page":"297","DOI":"10.5414\/CPP48297","article-title":"Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis","volume":"48","author":"Fasanmade","year":"2010","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2020043000063130100_CIT0028","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/gut.16.8.579","article-title":"Assessment of severity in colitis: a preliminary study","volume":"16","author":"Lennard-Jones","year":"1975","journal-title":"Gut"},{"key":"2020043000063130100_CIT0029","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1111\/j.1572-0241.2000.02186.x","article-title":"Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis","volume":"95","author":"Rowe","year":"2000","journal-title":"Am J Gastroenterol"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/24\/6\/1291\/33142280\/izx105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/24\/6\/1291\/33142280\/izx105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T04:14:09Z","timestamp":1588220049000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/24\/6\/1291\/4916098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,1]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,3,1]]},"published-print":{"date-parts":[[2018,5,18]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izx105","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,6]]},"published":{"date-parts":[[2018,3,1]]}}}